<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521521</url>
  </required_header>
  <id_info>
    <org_study_id>TAX_FR1_236</org_study_id>
    <nct_id>NCT00521521</nct_id>
  </id_info>
  <brief_title>Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer</brief_title>
  <acronym>TAX200006</acronym>
  <official_title>A Multicenter, Randomized, Phase II Study of the Combination of Docetaxel (TAXOTERE) and Concomitant Radiotherapy With or Without Cisplatin in Patients With Locally Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of the concomitant combination of radiotherapy and docetaxel with or
      without cisplatin in terms of objective response rates (WHO criteria).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rates</measure>
    <time_frame>evaluated 8 weeks after the end of radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the responses and overall survival</measure>
    <time_frame>time until progression</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>docetaxel and cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel and cisplatin</intervention_name>
    <arm_group_label>docetaxel and cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with locally advanced head and neck cancer (T3 and T4 tumors), epidermoid,
             histologically proven without metastasis; the primitive site of which is the oral
             cavity, the oropharynx, the hypopharynx or the larynx.

          -  Locally advanced tumors which are inoperable, or operable but the patient refuses
             surgery.

          -  Age ≥ 18 years and ≤ 70 years.

          -  PS &lt; 2.

          -  Satisfactory hematological, hepatic and renal functions: (PN ≥ 2000/mm3, platelet
             count ≥ 100,000/mm3, hemoglobin ≥ 10g/dl, serum creatinine ≤ 120 µmol/l or creatinine
             clearance ≥ 60 ml/mn, normal total bilirubin, AST (SGOT) and ALT (SGPT) ≤ 2.5 x the
             upper limit of normal (ULN) of each center, PAL ≤ 5 x LNS; patients with AST or ALT &gt;
             1.5 x LNS combined with PAL &gt; 2.5 x LNS will not be eligible for this trial.

        Exclusion Criteria:

          -  Any metastases (other than cervical ganglia).

          -  Cancer of the cavum and the facial structure.

          -  Any previous chemotherapy or radiotherapy, irrespective of the reason.

          -  Any surgery for epidermoid carcinoma in the upper aerodigestive tracts.

          -  Weight loss ≥10% of total body weight during the last 3 months.

          -  Any other previous cancer excepting in situ or cutaneous cervical cancer
             (spinocellular or basocellular).

          -  Pregnant or nursing women; women of childbearing potential must use an appropriate
             method of contraception.

          -  Poorly controlled progressive infection.

          -  Peripheral neuropathy with NCI grade ≥ 2.

          -  Neurological or psychiatric disease (dementia, seizures, etc.) that is not compatible
             with good understanding and sufficient compliance with treatment.

          -  Any other poorly controlled progressive disease, such as heart failure, symptomatic
             cardiac rhythm disorders, progressive angina pectoris, or respiratory impairment.

          -  Any other concomitant investigational treatment.

          -  Any other concomitant anticancer treatment.

          -  Allergy to polysorbate 80.

          -  Definitive formal contraindication to corticosteroids.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie SEBILLE, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2007</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

